Search | Page 13 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. ASH 2012 - Reviewing MDS Progress from Research and Clinical Perspectives

    ... drugs that impact DNA methylation (e.g., azacytidine, decitabine ) and drugs that impact histone acetylation (e.g., vorinostat, ...

    Interview last updated 02/01/2013 - 4:22pm.

  2. Aplastic Anemia and MDS Overlap Syndrome

    ... agents, azacitidine (Vidaza®) and decitabine (Dacogen®), which of course are not used in aplastic anemia. ...

    Interview last updated 05/13/2015 - 8:37am.

  3. MDS and MDS/MPN: Past, Present, and Future 2014 American Society of Hematology (ASH) Satellite Symposium Summary for Patients and Families

    ... agents (HMAs) azacitidine (Vidaza®) and decitabine (Dacogen®) inhibit DNA methylation so that DNA sequences can ...

    Page last updated 03/13/2015 - 5:00pm.

  4. Clinical Trial Basics

    ... bone marrow failure diseases. These include: decitabine (Dacogen) deferasirox (Exjade) lenalidomide ...

    Page last updated 01/20/2015 - 4:58pm.

  5. Clinical Trial Basics

    ... bone marrow failure diseases. These include: decitabine (Dacogen) deferasirox (Exjade) lenalidomide ...

    Page last updated 01/20/2015 - 4:46pm.

  6. Resistance to Hypomethylating Agents in the Treatment of MDS

    ... agents (HMA), azacitidine (Vidaza®), and decitabine (Dacogen®)? The overall response rate to HMA based ... that enzyme is called uridine cytidine kinase (UCK), and for decitabine, it’s called deoxycitadine kinase (DCK). So these kinases causing ...

    Interview last updated 06/17/2014 - 9:15am.

  7. Treating Higher-Risk Myelodysplastic Syndromes

    ... like azacitidine (Vidaza®) or decitabine (Dacogen®). If patients have very high-risk MDS, bordering on ... standard of care treatments for MDS includes azacitidine, decitabine, or lenalidomide (Revlimid®). Clinical research with new ...

    Interview last updated 05/18/2012 - 1:55pm.

  8. Understanding Prognosis in MDS

    ... the hypomethylating agents—azacitidine (Vidaza®) and decitabine (Dacogen®)—and IPSS doesn’t take the effect of these into ...

    Interview last updated 05/02/2012 - 4:36pm.

  9. Lower-Risk MDS: Diagnosis and Treatment Options

    ... agent, either azacitidine (Vidaza®) or decitabine (Dacogen®). Also, for patients with anemia for whom the ...

    Interview last updated 05/18/2012 - 1:28pm.